Evidence map›Paper›PMID 42790341›Full record

ReviewNuclear medicine and biology2026

Automated clinical production, dosimetry estimates and preclinical safety considerations for clinical translation of a SOAT1-targeted PET imaging agent.

Gina Kaup, Tanpreet Kaur, Bradford D Henderson, Wade P Winton, James R Hill, David M Raffel, Jenelle Stauff, Ka Kit Wong, Allen F Brooks, Xia Shao and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nuclear medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gina KaupDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States; Department of Medicinal Chemistry, The University of Michigan, Ann Arbor, MI, 48109, United States.
Tanpreet KaurDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Bradford D HendersonDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Wade P WintonDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
James R HillDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, 4072, Australia.
David M RaffelDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Jenelle StauffDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Ka Kit WongDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Allen F BrooksDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Xia ShaoDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Gary D HammerEndocrine Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, 48109, United States.
Benjamin L VigliantiDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.
Peter J H ScottDivision of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States; Department of Medicinal Chemistry, The University of Michigan, Ann Arbor, MI, 48109, United States; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States. Electronic address: pjhscott@umich.edu.

Funding

NHLBI NIH HHS F31 HL188955
6 · The paper itself

Abstract

backgroundSterol O-acyl transferase 1 (SOAT1) esterifies free cholesterol for storage in the adrenal glands and macrophages. The SOAT1 inhibitor, nevanimibe, has previously been investigated as a therapeutic in preclinical models of atherosclerosis and in clinical trials for adrenal diseases. Previously, our lab radiolabeled nevanimibe with carbon-11 to image hypercholesteremic mouse models via PET, and its biodistribution was characterized in rats. Here, we establish an automated production method for [

methodsThree process verification batches were completed in sequence using the same radiolabeling protocol. Using a GE TRACERlab

results[

conclusionsThese findings support further investigation of [

Indexed as

Clinical translationHuman-equivalent dosePETSOAT1 inhibitor

Identifiers

PMID42790341
PMCPMC13623080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.